MacroGenics | MGNX - Operating Expenses



MacroGenics reported $59M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Amgen USD 6.52B 337M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Daiichi Sankyo JPY 377.89B 57.19B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Genmab DKK 565M 38M Jun/2025
Geron USD 61.49M 5.18M Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
MacroGenics USD 59M 23.06M Jun/2025
Merck USD 9.44B 217M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Xencor USD 76.78M 865K Jun/2025